Tafamidis is first FDA-approved drug to treat potentially fatal disease
New podcast episode ranges from genetics insights to patient selection for tafamidis
Progress in quest for autoimmune mechanisms behind idiopathic dilated CM
When a patient’s and a program’s 30-year anniversaries intersect
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Treating peripartum cardioyopathy with advanced therapies